Should We Buy a Competitor?
in Insurance Brokers

The short answer

Acquisitions fail when the books of business cannot be combined without losing renewal retention, and the integration cost is the number least likely to have been estimated. For insurance brokers, this shows up in a particular place. The numbers that carry the answer are 19.0 and 91.2, and the complication specific to this industry is that 71 percent of revenue flows through carrier commissions while shifting an incremental 8 percent to fees would require replacing 142 renewal accounts and cut near-term margin by 1.8 to 2.3 points. The general version of this problem and the one you are actually in have different first moves.

The case for buying a competitor is usually built on revenue synergies from combining commissions and fees, which are the least reliable category of benefit and the slowest to arrive. Cost synergies from standard commissions are more predictable, and the honest ones are usually smaller than the model assumes.

The numbers that decide most outcomes are 19.0, 91.2, 664, 31 — systems conversion, people overlap, customer disruption to the 47.8 million dollars in total revenue from commissions and fees, and the management attention diverted from the existing book for a year or more. Integration cost is routinely omitted because it is hard to estimate and does not appear on either broker's accounts.

The disciplined version asks what specifically you get that you could not build or buy more cheaply another way, such as adding risk-control or captive feasibility capability, and what the business looks like if none of the revenue synergies materialise, leaving 71 percent of revenue flowing through carrier commissions.

How to tell this is actually your problem

These three together are the signature. One on its own usually points somewhere else.

✓ The rationale leans on cross-selling risk-control and captive feasibility to each other's renewal accounts
✓ Integration is described but the cost of replacing 142 accounts to shift 8 percent to fees is not modelled
✓ The acquisition is partly motivated by the core book showing stalled growth in contingent commissions

The move that usually makes it worse. Underwriting the deal on revenue synergies from shifting to fees, which typically arrive late, smaller than modelled, or not at all and cut near-term margin by 1.8 to 2.3 points.

Who this is for — and who it is not

It is for you if you run or finance an insurance broker and the rationale leans on cross-selling to each other's customers. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

What this looks like when the analysis is actually run

Below is an excerpt from a real run of this analysis on an insurance broker. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.

The subject is Kesterline Risk Partners, a sample company profile used for testing rather than a customer — 47.8 million dollars in total revenue from commissions and fees.

This is one move out of a full analysis. Read a complete report — every page, no email required.

What the engine does with this question

This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For insurance brokers it works through 19.0, 91.2, 664 and 31, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.

Questions people ask about this

How do I value a competitor?

Twice — once standalone, and once for what it is worth specifically to you. The gap between those is the most you can pay and still create value, and it is usually narrower than expected.

Are cost or revenue synergies more reliable?

Cost, substantially. They are within your control and can be scheduled. Revenue synergies depend on customers behaving as modelled, which is the assumption most often wrong.

What is the most common reason acquisitions fail?

Integration consuming more management attention than anyone budgeted, so that both businesses underperform during the period the deal was supposed to be paying back.

Is this different in insurance brokers than in other industries?

Materially, yes. 71 percent of revenue flows through carrier commissions while shifting an incremental 8 percent to fees would require replacing 142 renewal accounts and cut near-term margin by 1.8 to 2.3 points — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 19.0, 91.2, 664, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for an insurance broker?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 19.0 and 91.2. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.